ClinicalTrials.gg
RecruitingNCT07404865UPSTREAM SjDUpdated Oct 19, 2026

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

A Phase 3 interventional study of Telitacicept and Placebo in Primary Sjogren's Disease, sponsored by Vor Biopharma. Recruiting at 49 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Vor Biopharma · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Updated Oct 19, 2026First site in Georgia6 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 111 studies in Sjogren's Syndrome with a site in United States — 23 open to participants now, 29 under way, 8 of them phase 3. Sjogren's Syndrome · United States.

Planned enrollment
16th of 76
250 · median 57
Started
2026
with 6 others
Phase 3
12 of 111
3 open now
Primary completion
2028-12
later than 15 of 27 live
Registered
106th of 111
by date

Among the 111 studies in Sjogren's Syndrome with a site in United States, this one is the 16th largest by planned enrollment of the 76 interventional ones that give a count, is one of 7 that started in 2026, is one of 12 in phase 3, reaches primary completion later than 15 of the 27 other live ones, and was the 106th registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

23 of the 111 studies in Sjogren's Syndrome with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Sjogren's Syndrome with a site in United States, or all of them as a file.
02

Study summary

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease (UPSTREAM SjD)

Read the detailed description

Telitacicept (RC18) is a recombinant fusion protein designed to target B-cell-mediated immune pathways. It consists of the extracellular domain of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) linked to the Fc portion of human immunoglobulin G1 (IgG1).

Telitacicept binds with high affinity to the cytokines B-lymphocyte stimulator (BLyS, also known as BAFF) and A Proliferation-Inducing Ligand (APRIL). By binding these soluble factors, telitacicept prevents their interaction with cell-surface receptors on B cells, including TACI, B-cell maturation antigen (BCMA), and BAFF receptor (BAFF-R).

This inhibition reduces BLyS/APRIL signaling, leading to decreased B-cell survival, reduced differentiation of B cells into immunoglobulin-producing plasma cells, and lowering of autoantibody production, increased BLyS and APRIL levels, B-cell hyperactivity, and autoantibody production are associated with multiple autoimmune diseases.

Modulation of the BLyS/APRIL pathway is intended to reduce pathogenic B-cell activity and downstream immune effects that contribute to disease manifestations in Sjogren's disease and other B-cell-mediated autoimmune conditions.

03

Conditions studied

  • Primary Sjogren's Disease

Browse trials for

Keywords

  • Sjögren's Disease
  • pSD
  • Primary Sjogren's Syndrome
  • Sjogren's Syndrome
  • SjD
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 18 to 75 years of age (both inclusive) at screening
  2. Participants must meet the 2016 American College of Rheumatology (ACR)/EULAR classification criteria for primary Sjogren's Syndrome at the time of screening.
  3. ESSDAI ≥5 at screening (score calculated excluding renal, pulmonary and neurological domains)
  4. Participants are seropositive for antibodies to Sjogren's Syndrome A (SSA)/Anti-Sjogren's Syndrome A (Ro) at the Screening Visit.

Additional inclusion criteria are defined in the protocol

Exclusion criteria

Exclusion Criteria:

  1. Participants who have a systemic disease other than Primary Sjogren's Disease, such as rheumatoid arthritis, systemic lupus erythematosus, or systemic sclerosis, that can better explain the majority of the symptoms (i.e., secondary Sjogren's Disease)
  2. Participants who have another autoimmune disease or inflammatory condition that could interfere with assessment of response of Primary Sjogren's Disease to therapy (e.g., systemic sclerosis, inflammatory bowel disease, gout).
  3. Participants with severe fibromyalgia that could interfere with the assessment of response of Primary Sjogren's Disease to therapy
  4. Active life-threatening or organ-threatening complications of Primary Sjogren's Disease at the time of screening based on investigator evaluation
  5. Significant, uncontrolled medical disease in any organ system not related to Primary Sjogren's Disease (e.g., poorly controlled asthma, cardiovascular disease, accelerated hypertension, major depression, etc.) that in the opinion of the investigator would preclude participant participation.

Additional exclusion criteria are defined in the protocol

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Telitacicept

    Telitacicept

    Biological: Telitacicept

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • BiologicalTelitacicept

    Subcutaneous injection

    Also known as: RC18, RC18-L

  • DrugPlacebo

    Subcutaneous injection

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of telitacicept versus placebo at Week 48 in the change from baseline in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at Week 48.

    Change from baseline in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at Week 48.

    Time frame: Week 48

Secondary outcomes

  1. To evaluate the efficacy of telitacicept versus placebo at Week 48 in the treatment of adult participants with pSD.

    To evaluate the efficacy of telitacicept versus placebo at Week 48 in the treatment of adult participants with pSD.

    Time frame: Week 48

  2. To evaluate the efficacy of telitacicept versus placebo in improving glandular function during the trial.

    Change from baseline in the stimulated whole salivary flow at Week 48.

    Time frame: Week 48

  3. To evaluate the effect of telitacicept versus placebo in improving patient-reported outcomes (i.e., how participants feel and function) during the trial.

    Change from baseline in the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) score at Week 48

    Time frame: Week 48

  4. To evaluate the efficacy of telitacicept versus placebo at Week 48 in the change from baseline in the physician's global assessment of disease activity (Physician GDA) score at Week 48

    Change from baseline in the physician's global assessment of disease activity (Physician GDA) score at Week 48

    Time frame: Week 48

  5. To evaluate the efficacy of telitacicept versus placebo at Week 48 in the change from baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) score at Week 48

    Change from baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) score at Week 48

    Time frame: Week 48

  6. To evaluate the efficacy of telitacicept versus placebo at Week 48 in the change from baseline in the participant's global assessment of disease activity (Patient GDA) at Week 48.

    Change from baseline in the participant's global assessment of disease activity (Patient GDA) at Week 48.

    Time frame: Week 48

07

Study locations

49 of 49 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Dec 2028, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 12, 2026
StartActual
Feb 26, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Jan 2029
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added — first site in Georgia
Show 6 added (4 United States, 2 Georgia)
  • Clever Medical Research · Miami, United States
  • Duke University Medical Center · Durham, United States
  • Oklahoma Medical Research Foundation · Oklahoma City, United States
  • Clinical Research of Philadelphia, LLC · Philadelphia, United States
  • Innova LLC · Tbilisi, Georgia
  • The First Medical Center LLC · Tbilisi, Georgia
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    6 sites added — first site in Georgia
    Show 6 added (4 United States, 2 Georgia)
    • Clever Medical Research · Miami, United States
    • Duke University Medical Center · Durham, United States
    • Oklahoma Medical Research Foundation · Oklahoma City, United States
    • Clinical Research of Philadelphia, LLC · Philadelphia, United States
    • Innova LLC · Tbilisi, Georgia
    • The First Medical Center LLC · Tbilisi, Georgia

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07404865
Lead sponsor
Vor Biopharma
Responsible party
Sponsor
First posted
Feb 12, 2026
Start date
Feb 26, 2026
Primary completion
Dec 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Oct 19, 2026

Study contacts

Jeremy Sokolove
Contact
Study@vorbio.com
6176556580

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telitacicept

Start the discussion